Table 4 Univariate analyses of potential prognostic factors for distant metastasis-free survival (DMFS)
Factors | DMFS at 1 year (%) | DMFS at 2 years (%) | DMFS at 5 years (%) | p-value |
|---|---|---|---|---|
Age | ||||
65–74 years | 60 | 45 | 23 | |
75–84 years | 73 | 61 | 25 | |
≥ 85 years | 60 | 30 | 30 | 0.50 |
Gender | ||||
Female | 71 | 57 | 37 | |
Male | 63 | 47 | 20 | 0.20 |
ECOG score | ||||
0–1 | 65 | 50 | 25 | |
2–3 | 62 | 46 | - | 0.50 |
Charlson Comorbidity Index | ||||
≤ 5 | 62 | 53 | 39 | |
> 5 | 64 | 47 | 19 | 0.30 |
Clinical tumor classification (cT) | ||||
1 | 50 | - | - | |
2 | 75 | 50 | 17 | |
3 | 66 | 52 | 28 | |
4 | 44 | 30 | 15 | 0.80 |
Clinical lymph node classification (cN) | ||||
Nodal negative (N0) | 75 | 54 | 19 | |
Nodal positive (N +) | 62 | 48 | 25 | 0.60 |
Tumor stage (AJCC) | ||||
1–3 | 65 | 48 | 25 | |
4a | 63 | 52 | 14 | 0.60 |
Localization of the primary tumor | ||||
15–32 cm distance from the incisors | 75 | 64 | 44 | |
33 cm distance from the incisors until gastroesophageal junction | 61 | 44 | 19 | 0.10 |
Administration of full-dose RT | ||||
yes | 17 | 17 | - | |
no | 68 | 52 | 24 | 0.20 |
Cumulative dose of RT (EQD2) | ||||
≤ 50 Gy | 59 | 46 | 32 | |
> 50 Gy | 71 | 53 | 17 | 0.70 |
Administration of non-modified, full-dose chemotherapy | ||||
yes | 67 | 59 | 38 | |
no | 63 | 44 | 18 | 0.26 |
Treatment concept | ||||
Neoadjuvant CRT followed by surgical resection | 72 | 63 | 46 | |
Definitive RT / CRT | 60 | 41 | 14 | 0.009 |